|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNISA996320245903316 |
|
|
Titolo |
Treatment of tuberculosis [[electronic resource] ] : guidelines |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Geneva, : World Health Organization, 2010 |
|
|
|
|
|
|
|
ISBN |
|
1-282-76081-5 |
9786612760815 |
92-4-068535-9 |
|
|
|
|
|
|
|
|
Edizione |
[4th ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (159 p.) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Antitubercular agents |
Tuberculosis - Chemotherapy |
Patient compliance |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Previous editions had different title : "Treatment of tuberculosis : guidelines for national programmes". |
"WHO/HTM/TB/2009.420." |
"World Health Organization, Stop TB Dept." |
|
|
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
COVER; COPYRIGHT; Contents; Abbreviations; Acknowledgements; Foreword; Executive summary; Introduction; Case definitions; Standard treatment regimens; Monitoring during treatment; Co-management of HIV and active TB disease; Supervision and patient support; Treatment of drug-resistant tuberculosis; Treatment of extrapulmonary TB and of TB in special situations; Annexes; Essential first-line antituberculosis drugs; Summary of evidence and considerations underlying the recommendations; TB treatment outcomes; Suggestions for future research |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
The World Health Organization's Stop TB Department has prepared this fourth edition of Treatment of Tuberculosis: Guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition. First, the recommendation to discontinue the regimen based on just 2 months of rifampicin (2HRZE/6HE) and change to the regimen based on a full 6 months of rifampicin (2HRZE/4HR) will reduce the number of relapses and failures. This will alleviate patient suffering resulting from |
|
|
|
|